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Mean (%) 0.58 0.15 0.39 
SD (%) 0.98 0.08 0.38 
 
Conclusions: The small differences allows us to state that 
the safety margin is adequate for a safe treatment. However, 
a more precise feedback to the TPS would be appropriate to 
reduce this margin of 3 mm. 
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Purpose/Objective: The aim of this study is to quantify by 
MOSFET dosimetry techniques in vivo dosimetric uncertainties 
in patients undergoing treatment with radical intent 
brachytherapy high dose rate prostate organ-confined at 
different levels of the prostatic urethra cancer and the 
anterior face of the rectum. 
Materials and Methods: A strip with five micro MOSFET (Best 
Medical Canada) was introduced through a urethral catheter, 
performing simultaneous dose measurements at five points 
along the prostatic urethra: the first in the bladder wall, the 
second in the middle of the prostate gland, the third toward 
the apex, the fourth in the bulbar urethra and the fifth away 
from the others.We also placed simultaneously two micro 
MOSFET 2 cm apart from each other on the anterior rectal 
wall using an endotracheal tube sealed at its end. Finally, we 
planned the treatments with Prostate Oncentra® treatment 
planning system, creating dose points at the positions 
identified above and comparing the results obtained with the 
measurements. Between November 2013 and May 2014, we 
performed 29 measurements in 23 patients with localized 
prostatic adenocarcinoma, 18 of them made with rectal 
protection using hyaluronic acid.  
Results: The differences between the MOSFET measurements 
and the calculated doses were between 0.34% and 21% with a 
standard deviation ranging from 1 to 19%. 
Conclusions: The in vivo dosimetry technique used in our 
study with MOSFET to measure the doses delivered to the 
urethra and the anterior perirectal fat can be used to 
identify patients with an increased risk of treatment 
complications and possibly modify the implantation 
procedure. 
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Purpose/Objective: A retrospective analysis in 489 
consecutives prostate cancer patients have been made, for 
evaluating the toxicity of different multimodality 
radiotherapy approaches for organ confined prostate cancer 
in one single Institution with ED in different risk groups. 
Materials and Methods: From September 2004 to December 
2011, we have treated in our Department in a curative 
attempt 489 patients. We have excluded of this analysis 30 
patients with recurrences after radical prostatectomy, and 
177 patients without personal follow-up. The rest, 282 
patients has been the target of the present study. Our 
protocol has been designed according to uniformity on the 
risk classification of prostate adenocarcinoma with ED. That’s 
included external radiotherapy (EBRT)(72.00 Gy) 18 pts, or 
Low dose rate Brachytherapy LDRBT (145/160 Gy) 59 pts in 
low risk (LR) patients, IMRT-IGRT (75.60 Gy) 21 pts or 
combined treatment (3D-EBRT over prostate and seminal 
vesicles, 45 Gy + LDRBT (100/108 Gy) 83 pts in intermediate 
risk (IR) patients, and IMRT-IGRT (79.20 – 81 Gy) 52 pts or 
combined treatment (IMRT over pelvis 50.40 cGy and High 
dose rate brachytherapy 2 x 9.5 Gy (HDRBT) 49 pts in high 
risk (HR) patients. Median age of the whole group was 71 
years (range 46-87 y). Median PSA was 9.74 ng/ml (range 2.5-
500 ng/ml). Median Gleason 6 (range 2-10). In 191 pts (68%) a 
MRI for staging was made.  
Results: At the time of this analysis, the median follow up 
was 50 months (range 3-112 mo). Cause specific survival was 
98%. Local control was achieved in 271 pts (96%). Biochemical 
control 272 pts (96.5%). We have evidenced lymph node 
failure in 7 pts (2.5%). Distance failure in 17 pts (6%). Late GI 
toxicity has been evaluated following the CTCVA 4.0 criteria 
and it is represented in Table 1: Median time for GI toxicity 
was 11 months (1-40 months). Median time for GU toxicity 
was 2 months (1-48 months). All patients with rectitis G3 
were treated with EBRT (3D or IGRT). Eight of them have 
received more than 79.20 Gy. 
 
GENITOURINARY (GU) 
TOXICITY GRADE 3 
# TREATMENT 
Hematuria 3 p (1.1%) 2 p IGRT and 1p with 
3D+ LDRBT 
Cystitis 1p (0.4%) IGRT 
Urinary obstruction 2p (1.1%) LDRBT 
Urethral stenosis 4p (1.4%) 1p IGRT and 2p 3D + 
LDRBT 
Increased of the urinary 
frequency 
2p (0.7%) 1p IGRT and 1p 3D + 
LDRBT 
Urinary retention 1p (0.4%) IMRT + HDRBT 
GASTROINTESTINAL (GI) 
TOXICITY GRADE 3 
  
Diarrhea 1p (0.4%) IGRT 
Rectitis 19 p (7%) 4 p 3D/ 15 p IGRT 
 
Conclusions: In our experience, combination modalities with 
BT techniques escalating dose achieve more intensity 
treatments with high rate for both local and biochemical 
control a cause specific survival, with lesser toxic events, 
mainly related to gastrointestinal damage.  
   
